The FDA approved lonvoguran ziclumeran (lonvo-z), an in vivo CRISPR treatment for hereditary angioedema (HAE), after the therapy cleared Phase III and received BLA approval in September. The one-dose genome-editing program uses an mRNA-lipid nanoparticle delivery format designed to change disease biology with a single administration. The approval follows publication of successful Phase III HAELO trial results in The New England Journal of Medicine in June. The company’s approach aims to address the burden of unpredictable, potentially life-threatening swelling attacks that can impair quality of life and travel, school, and work. For biotech, the approval is a high-signal validation of in vivo CRISPR delivery at scale—potentially informing how other genome-editing programs will structure evidence packages, manufacturing, and post-approval follow-up.